All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Abivax
Enrolment target
322
Start
22 May 2023
What is this study about?
Co-primary endpoints: Proportion of subjects who achieve endoscopic improvement at week 8 and proportion of subjects with symptomatic remission at week 8.
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (14)
- —France
- —Spain
- —Italy
- —Germany
- —Belgium
- —Poland
- —Bulgaria
- —Croatia
- —Czechia
- —Hungary
- —Ireland
- —Lithuania
+2 more sites — see the official record for the full list.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.